The short course of gonadotropin-releasing hormone (GnRH) antagonists is used in assisted reproduction treatments, such as in vitro fertilization with intracytoplasmic sperm injection (IVF-ICSI). But there are some circumstances in which we can take special advantage. This process seeks to optimize the chances of success for our patients.
A primary indication for using short cycle with antagonists is the need to prevent premature ovulation during the process of controlled ovarian stimulation. Gonadotropin-releasing hormone (GnRH) antagonists temporarily block the release of luteinizing hormone (LH - induces ovulation), thus preventing ovulation before the ovarian follicles are mature and ready for follicular puncture. This is crucial to maximize the amount of high quality eggs available for our treatments and therefore the chances of success.
In addition, couples who have a history of suboptimal ovarian response to previous treatments may benefit from short cycling with antagonists. The approach allows greater flexibility in regulating ovarian response, which may result in a greater number of eggs available for fertilization.
Compared to long cycles involving GnRH agonists and subsequent ovulation induction with hCG, short cycling with antagonists reduces the risk of ovarian hyperstimulation syndrome (OHSS). By minimizing the need for ovulation induction with hCG, the likelihood of an excessive and potentially dangerous ovarian response is decreased.
This is in summary the indications for the use of short cycle GnRH antagonists, but we cannot forget that each patient is unique and requires a detailed medical evaluation by your specialist to determine the most appropriate treatment strategy for your particular situation.
